The Annals Summaries of the Latest Medical Research!
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     


Published Online, 9 November 2004, www.theannals.com, DOI 10.1345/aph.1E166.
 The Annals of Pharmacotherapy: Vol. 38, No. 12, pp. 2035-2040. DOI 10.1345/aph.1E166
© 2004 Harvey Whitney Books Company.
This Article
Right arrow Résumé Freely available
Right arrow Extracto Freely available
Right arrow Full Text
Right arrow PDF
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Manley, H. J
Right arrow Articles by Welch, C. L
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Manley, H. J
Right arrow Articles by Welch, C. L

INFECTIOUS DISEASES

Intraperitoneal Cefazolin and Ceftazidime Effects on Human Peritoneal Mesothelial Cell Release of Cancer Antigen–125

Harold J Manley, PharmD BCPS

at time of writing, Assistant Professor of Pharmacy Practice, School of Pharmacy, University of Missouri, Kansas City, MO; now, Associate Professor of Pharmacy Practice, Albany College of Pharmacy, Albany, NY

Rowland J Elwell, PharmD

Assistant Professor of Pharmacy Practice, Albany College of Pharmacy

George R Bailie, PharmD PhD

Professor of Pharmacy Practice, Albany College of Pharmacy

Charles L Welch, PhD

Director of Laboratory, Research Medical Center, Kansas City

Reprints: Harold J Manley PharmD BCPS, Albany College of Pharmacy, 106 New Scotland Ave., Albany, NY 12208-3492, fax 518/445-7302, ManleyH{at}ACP.edu

BACKGROUND: Intraperitoneal (IP) cefazolin and ceftazidime are recommended as empiric treatment for peritoneal dialysis (PD)–associated peritonitis. Human peritoneal mesothelial cells (HPMCs) may be affected by high IP cefazolin and ceftazidime concentrations. Peritoneal dialysate cancer antigen–125 (CA-125) appearance rate can be used to measure HPMC damage.

OBJECTIVE: To determine whether IP cefazolin and ceftazidime increase peritoneal CA-125 appearance rate.

METHODS: The study consisted of 2 phases. In phase I, no antibiotic was administered, and in phase II, patients received IP cefazolin and ceftazidime (15 mg/kg rounded to nearest 100 mg). Phase II occurred immediately after phase I. Each phase used a 4-hour dwell time with 2 L of dextrose 2.5% dialysate. Dialysate samples were collected at 0, 0.5, 1, 2, and 4 hours during each phase. Samples were assayed for CA-125, and CA-125 appearance rate was calculated.

RESULTS: Thirteen patients were recruited (7 men; aged 44.0 ± 16.0 y). The mean ± SD (range) CA-125 dialysate concentration after phases I and II were 6.6 ± 3.7 U/mL (2.3–15.0) and 6.4 ± 3.8 U/mL (1.6–13.8), respectively (p = 0.46). The CA-125 appearance rate after phases I and II were 51.9 ± 31.3 U/min/1.73 m2 (13.8–113.0) and 50.5 ± 32.9 U/min/1.73 m2 (11.0–104.0), respectively (p = 0.57). The slopes of the regression lines of CA-125 appearance rate were not significantly different between phases I and II.

CONCLUSIONS: These findings demonstrate that concurrently administered IP cefazolin and ceftazidime have no effect on HPMC release of CA-125 in non-infected PD patients.

Key Words: cancer antigen–125, cefazolin, ceftazidime, human peritoneal mesothelial cell

Published Online, November 9, 2004. www.theannals.com, DOI 10.1345/aph.1E166




homecopy help contact us subscription past issues search current issue
Copyright © 2004 by Harvey Whitney Books Company.